OncoMatch/Clinical Trials/NCT06712927
Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases
Is NCT06712927 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Ipilimumab and Nivolumab + Relatlimab FDC for melanoma.
Treatment: Ipilimumab · Nivolumab + Relatlimab FDC — This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-CTLA-4 therapy
Exception: Prior CTLA-4 therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment
No prior anti-CTLA-4...therapy for unresectable stage III/IV melanoma. Prior CTLA-4...therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment.
Cannot have received: anti-PD-1 therapy
Exception: Prior PD-1 therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment
No prior...anti-PD-1...therapy for unresectable stage III/IV melanoma. Prior...PD-1...therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment.
Cannot have received: anti-LAG-3 therapy
Exception: Prior LAG-3 therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment
No prior...anti-LAG-3 therapy for unresectable stage III/IV melanoma. Prior...LAG-3 therapy in the neoadjuvant or adjuvant setting is acceptable if >6 months since last treatment.
Cannot have received: whole brain radiation therapy
Prior whole brain radiation therapy (WBRT)
Cannot have received: investigational drug
Investigational drug use within 14 days (or 5 half-lives, whichever is longer) of the first dose of study treatment
Lab requirements
Kidney function
Estimated creatinine clearance (eCrCl) ≥ 30 mL/min using the Cockcroft-Gault formula
Liver function
ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5x ULN
Adequate organ function as assessed by the following parameters: ALT and AST ≤ 3 × ULN; patients with liver metastasis ≤ 5 × ULN; eCrCl ≥ 30 mL/min; total bilirubin ≤ 1.5x ULN OR direct bilirubin ≤ ULN for participants with total bilirubin levels >1.5x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford University · Palo Alto, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify